Shanghai Abelzeta Ltd.

This early-phase study tests a new treatment called C-CAR031 for people with advanced squamous cell lung cancer that has not responded to standard therapies. The treatment uses a patient's own immune cells, modified in a lab to target a protein called GPC3 found on cancer cells. …

This study tests a new treatment called C-CAR031 for people with advanced or recurrent liver cancer that has not responded to at least two prior therapies. The treatment uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. …

This study tests a new treatment called C-CAR039 (Prizlon-cel) for people with large B-cell lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to attack two targets (CD19 and CD20) on cancer cells. The study h…

This early-phase study tests a new treatment called A-CAR032 for men with advanced prostate cancer that has stopped responding to standard hormone therapy. The treatment uses specially engineered immune cells to attack the cancer. The main goal is to check safety, but researchers…